XNASINKT
Market cap28mUSD
Jan 10, Last price
0.73USD
1D
-6.28%
1Q
8.94%
IPO
-93.75%
Name
Mink Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-22m
L-9.37%
CFO
-16m
L-16.45%
Earnings
Jun 12, 2025
Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,704,743 | ||||
Cost of revenue | 23,126 | 30,980,227 | |||
Unusual Expense (Income) | |||||
NOPBT | (23,126) | (28,275,484) | |||
NOPBT Margin | |||||
Operating Taxes | (3,211) | ||||
Tax Rate | |||||
NOPAT | (23,126) | (28,272,273) | |||
Net income | (22,458) -9.37% | (24,780) 7.21% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (478) | 293,366 | |||
BB yield | 1.30% | -333.80% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 11,205 | 9,190 | |||
Net debt | (3,367) | (19,636) | |||
| Cash flow | |||||
Cash from operating activities | (15,763) | (18,867) | |||
CAPEX | (74) | (250) | |||
Cash from investing activities | (74) | (250) | |||
Cash from financing activities | (407) | (156) | |||
FCF | (15,209) | (28,272,733) | |||
| Balance | |||||
Cash | 3,367 | 19,636 | |||
Long term investments | |||||
Excess cash | 3,367 | ||||
Stockholders' equity | (133,828) | (111,231) | |||
Invested Capital | 126,977 | 120,020 | |||
ROIC | |||||
ROCE | 337.59% | ||||
| EV | |||||
Common stock shares outstanding | 34,360 | 33,673 | |||
Price | 1.07 -59.00% | 2.61 -41.48% | |||
Market cap | 36,765 -58.17% | 87,886 -41.14% | |||
EV | 33,398 | 68,251 | |||
EBITDA | (22,921) | (28,275,363) | |||
EV/EBITDA | |||||
Interest | 253 | ||||
Interest/NOPBT | |||||